Vicente Vicente Selected Research

Acenocoumarol

3/2018	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality.
1/2018	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
1/2018	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients.
1/2018	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials.
11/2015	The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vicente Vicente Research Topics

Disease

36	Thrombosis (Thrombus) 12/2023 - 08/2002
29	Hemorrhage 01/2022 - 01/2003
29	Atrial Fibrillation 10/2021 - 09/2004
24	Neoplasms (Cancer) 12/2023 - 10/2004
18	Venous Thrombosis (Deep-Vein Thrombosis) 11/2021 - 08/2002
15	Stroke (Strokes) 11/2020 - 09/2006
14	Myocardial Infarction 11/2020 - 08/2002
13	Thrombophilia 03/2023 - 05/2008
12	Inflammation (Inflammations) 02/2021 - 09/2004
10	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022 - 05/2014
7	Ischemic Stroke 12/2019 - 09/2006
6	Neoplasm Metastasis (Metastasis) 12/2023 - 07/2005
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 07/2003
6	Breast Neoplasms (Breast Cancer) 10/2019 - 07/2003
5	Acute Coronary Syndrome 01/2018 - 12/2007
4	Colorectal Neoplasms (Colorectal Cancer) 12/2023 - 01/2020
4	Thrombocytopenia (Thrombopenia) 01/2023 - 11/2017
4	Venous Thromboembolism 02/2021 - 05/2008
4	Atherosclerosis 01/2021 - 09/2004
4	Vascular Diseases (Vascular Disease) 01/2021 - 03/2014
4	Lymphoma (Lymphomas) 01/2020 - 06/2012
4	Heart Failure 01/2018 - 03/2014
4	Thrombasthenia (Glanzmann Thrombasthenia) 11/2017 - 04/2002
3	Infections 01/2020 - 12/2004
3	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2020 - 10/2013
3	Thromboembolism 12/2019 - 06/2011
3	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2018 - 03/2016
3	Hypertension (High Blood Pressure) 11/2015 - 08/2010
3	Essential Thrombocythemia 12/2014 - 06/2009
3	Obesity 05/2014 - 01/2008
3	Wounds and Injuries (Trauma) 02/2014 - 09/2004
3	Necrosis 01/2013 - 02/2008
3	Melanoma (Melanoma, Malignant) 06/2009 - 01/2004
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/2023 - 06/2009
2	Inborn Genetic Diseases (Disease, Hereditary) 08/2022 - 01/2018
2	Disease Susceptibility (Diathesis) 01/2021 - 01/2019
2	COVID-19 01/2021 - 01/2021
2	Congenital Disorders of Glycosylation 10/2020 - 11/2019
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2020 - 02/2019
2	Disseminated Intravascular Coagulation 01/2020 - 01/2016
2	Pulmonary Embolism 12/2019 - 06/2010
2	Residual Neoplasm 10/2019 - 11/2014
2	Multiple Myeloma 02/2019 - 03/2008

Drug/Important Bio-Agent (IBA)

35	AntithrombinsIBA 03/2023 - 11/2003
20	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2006
18	AnticoagulantsIBA 10/2021 - 04/2007
13	Biomarkers (Surrogate Marker)IBA 12/2023 - 06/2011
12	Vitamin K FDA Link 11/2020 - 04/2012
10	Hemostatics (Antihemorrhagics)IBA 01/2022 - 03/2005
9	Inosine Triphosphate (ITP)IBA 01/2022 - 05/2014
9	MicroRNAs (MicroRNA)IBA 01/2021 - 03/2011
8	SerpinsIBA 01/2016 - 09/2004
6	Thrombin FDA Link 12/2023 - 03/2009
6	Factor XIII (Coagulation Factor XIII)IBA 09/2010 - 08/2002
5	von Willebrand FactorIBA 01/2021 - 06/2011
5	AcenocoumarolIBA 03/2018 - 11/2015
4	Factor XII (Hageman Factor)IBA 10/2020 - 12/2005
4	FibrinIBA 01/2018 - 04/2005
4	Warfarin (Coumadin)FDA LinkGeneric 01/2018 - 04/2012
4	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018 - 07/2008
4	Prothrombin (Factor II)IBA 01/2017 - 08/2002
4	factor V LeidenIBA 11/2010 - 05/2008
3	hepsinIBA 12/2023 - 06/2022
3	Serine Proteases (Serine Protease)IBA 12/2023 - 06/2022
3	Thrombopoietin ReceptorsIBA 08/2021 - 11/2019
3	DNA (Deoxyribonucleic Acid)IBA 02/2021 - 02/2014
3	Dacarbazine (DIC)FDA LinkGeneric 01/2021 - 01/2016
3	Heparin (Liquaemin)FDA LinkGeneric 01/2021 - 01/2016
3	Fibrinogen (Factor I)FDA Link 01/2021 - 09/2004
3	AntigensIBA 10/2020 - 12/2004
3	Adenosine Diphosphate (ADP)IBA 01/2020 - 05/2009
3	Protein CIBA 12/2019 - 04/2007
3	eculizumab FDA Link 11/2019 - 03/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2018 - 10/2004
3	Dabigatran FDA Link 01/2018 - 06/2015
3	EnzymesIBA 11/2017 - 12/2004
3	IntegrinsIBA 01/2016 - 07/2003
3	AnthracyclinesIBA 06/2015 - 02/2012
3	LipidsIBA 08/2010 - 08/2006
3	Integrin beta3 (GPIIIa)IBA 07/2010 - 04/2002
3	plasma protein Z (protein Z)IBA 04/2007 - 05/2005
3	Protease Inhibitors (Protease Inhibitor)IBA 04/2007 - 05/2005
2	venetoclaxIBA 12/2023 - 01/2023
2	Messenger RNA (mRNA)IBA 01/2023 - 01/2018
2	Factor XI (Plasma Thromboplastin Antecedent)IBA 10/2021 - 11/2019
2	LipopolysaccharidesIBA 01/2021 - 04/2005
2	fibrin fragment D (D-dimer)IBA 01/2021 - 06/2011
2	Congenital disorder of glycosylation type 1AIBA 10/2020 - 10/2013
2	CollagenIBA 01/2020 - 07/2008
2	Polysaccharides (Glycans)IBA 01/2020 - 01/2017
2	Estrogen ReceptorsIBA 10/2019 - 01/2018

Therapy/Procedure

30	Therapeutics 01/2023 - 02/2008
6	Drug Therapy (Chemotherapy) 06/2015 - 07/2005
5	Neoadjuvant Therapy 05/2022 - 11/2014
4	Thrombolytic Therapy 09/2010 - 08/2002
3	Platelet Transfusion (Blood Platelet Transfusions) 10/2018 - 01/2016
2	Molecular Targeted Therapy 12/2023 - 01/2023
2	Ligation 03/2023 - 04/2005
2	Aftercare (After-Treatment) 05/2022 - 03/2007
2	Splenectomy 01/2022 - 11/2019